Remedy Medical Properties and Kayne Anderson Real Estate Acquire Tennessee Oncology Proton Center

Franklin, TN — June 1st, 2026 — Remedy Medical Properties (“Remedy”) and Kayne Anderson Real Estate today announced the acquisition of Tennessee Oncology Proton Center, a 48,776-square-foot proton therapy facility.

Built in 2018, the facility includes three treatment rooms and capacity to treat up to 90 patients per day. The property is currently fully occupied.

Proton therapy is an advanced form of radiation treatment that can reduce radiation exposure to surrounding healthy tissue compared to traditional photon-based radiation therapy. Due to the specialized infrastructure required, including heavily shielded treatment vaults and significant capital investment, proton therapy centers are among the most complex outpatient oncology facilities in the healthcare real estate sector.

Richard Howell, Brett Levin, and Matt Jos of Blueprint represented the seller, a private family office, in the transaction.

“Our internal strategy team conducted extensive research that allowed us to make an informed investment decision,” said Joe Magliochetti, Chief Investment Officer at Remedy. “Positioned as a core specialty asset, we recognized both the strength of the tenancy and the long-term potential of this proton therapy center within the Tennessee Oncology and OneOncology care network.”

Richard Howell, Director at Blueprint, noted, “Marketing a single-use facility that many investors view as too specialized to trade was a unique experience, but we believed in this opportunity because Tennessee Oncology transformed a distressed asset into a true center of excellence in less than three years. With only 48 proton therapy centers across the country, this transaction is an exceptional outcome for our client and an important signal for the future of the sector.”

“The closing carries meaningful implications for existing proton center ownership groups across the country,” said Steve Thomes, Executive Managing Director and Head of Business Development at Blueprint. “For the health systems, regional providers, academic institutions, family offices, and private investor groups that own these assets, the transaction establishes a market reference point where one previously did not exist. When evaluating long-term capital strategies, there is now a documented path to monetize highly specialized clinical real estate outside of distressed scenarios. We are grateful to our client for the opportunity to advise them, and we look forward to applying these insights to the broader sector.”